skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

What major drug catalysts and events can you expect to see this quarter?

Download your free Biomedtracker/Meddevicetracker Q4 2019 Outlook Report, a data driven assessment of the likelihood of approval for an array of drugs. 

Get a view of what’s to come with an extract from the full report, containing:

Data for 33 drugs, diagnostics, and devices
Likelihood of Phase/PDUFA review success for each
Q4 expected large impact catalysts
A look back at the outcomes from the Q3 Outlook report
Overall Likelihood of Approval (LOA) based on phase, drug class, and disease group
Benchmarking data from Pharmapremia

JN2646_Cov_Ima_Q4_2019_Outlook_Report_Extract

Read also

  • Datamonitor Healthcare: data analysis and insight, Biomedtra...

    RNA Targeting Poised To Share The Spotlight With Gene Therapy

    By Daniel Chancellor

    As the biopharma industry concludes its annual pilgrimage to San Francisco for the JP Morgan investor conference, much of the talk around town inevitably was about gene therapies.

    Topics Cell and gene therapy

  • Datamonitor Healthcare: data analysis and insight, Biomedtra...

    Pricing and reimbursement of curative therapies continues to dominate ISPOR discussions

    By Louisa Joseph

    Commentators at the ISPOR Europe 2019 conference in Copenhagen debated the challenges that exist with valuing and financing potentially curative treatments, including cell and gene therapies, and cancer immunotherapies. With several recent regulatory approvals of high-cost advanced therapy medicinal products (ATMPs), discussion has ensued in earnest on how to determine their clinical value, and whether traditional reimbursement and health technology assessment (HTA) processes are sufficient to assess these innovative treatments.

    Topics

  • Meddevicetracker: medical device intelligence and forecasts

    Drug Delivery Inhalation Devices Report Extract

    Capture details about the worldwide market for COPD and asthma inhalation drug devices with Meddevicetracker’s “Drug Delivery: Inhalation Devices Report Extract: US, 5EU Markets, and Japan”.

;

Next steps

Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: